Ribavirin induced anaemia: The effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 9, 2014, Pages 2667-2676

  Refaat, Bassem ^a   Ashour, Tariq Helal ^a   El Shemi, Adel Galal ^a,b  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Anaemia; Erythropoietin hormone; Pegylated interferon ; Ribavirin and vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLECALCIFEROL; CREATININE; ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA; RIBAVIRIN; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MEAN CORPUSCULAR VOLUME; NONHUMAN; RAT; VITAMIN SUPPLEMENTATION;

EID: 84907848982     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Averhoff FM, Glass N and Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55 Suppl 1: S10-5.
2. Ghany MG, Strader DB, Thomas DL and Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
3. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013; 11: 1503-10.
4. Lange CM and Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-92.
5. Younossi ZM, Singer ME, Mir HM, Henry L and Hunt S. Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients. J Hepatol 2014; 60: 530-7.
6. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013; 13: 190.
7. Cure S, Bianic F, Gavart S, Curtis S, Lee S and Dusheiko G. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17: 65-76.
8. Sandokji AM, Sanai FM, Al-Ajlan AA and Al-Karawi MA. Interferon-ribavirin therapy for chronic hepatitis C: efficacy in Saudi patients. Saudi J Gastroenterol 2003; 9: 129-34.
9. Garcia TJ, Lara PH, Morimoto TP, Higasiaraguti M, Perejao AM and Ayub MA. Side effects of the hepatitis C treatment at the ABC application center. Rev Assoc Med Bras 2012; 58: 543-9.
10. McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML and Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-9.
11. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39: S3-8.
12. Keeffe EB and Kowdley KV. Hematologic side effects of PEG interferon and ribavirin. Management with growth factors. J Clin Gastroenterol 2005; 39: S1-2.
13. Kurschel E, Metz-Kurschel U, Niederle N and Aulbert E. Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes. Ren Fail 1991; 13: 87-93.
14. Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S and Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401-7.
15. Tarumi T, Sawada K, Sato N, Kobayashi S, Takano H, Yasukouchi T, Takashashi T, Sekiguchi S, Koike T. Interferon-alpha-induced apoptosis in human erythroid progenitors. Exp Hematol 1995; 23: 1310-8.
16. Kato K, Kamezaki K, Shimoda K, Numata A, Haro T, Aoki K, Ishikawa F, Takase K, Ariyama H, Matsuda T, Miyamoto T, Nagafuji K, Gondo H, Nakayama K, Harada M. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth. Br J Haematol 2003; 123: 528-35.
17. Sulkowski MS, Wasserman R, Brooks L, Ball L and Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50.
18. Tanaka H, Miyano M, Ueda H, Fukui K and Ichinose M. Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C. Clin Exp Med 2005; 5: 190-5.
19. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I and Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62: 1174-80.
20. Van Vlierbergh H, Delanghe JR, De Vos M and Leroux-Roel G, Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 911-6.
21. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
22. Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ; HCV Natural History Study Group. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005; 100: 299-307.
23. Martin P and Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 844-55.
24. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
25. Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371-9.
26. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.
27. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology 2013; 145: 1035-1044, e5.
28. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM; SPRINT-2 Trial Investigators. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57: 974-84.
29. Deicher R and Horl WH. Hormonal adjuvants for the treatment of renal anaemia. Eur J Clin Invest 2005; 35 Suppl 3: 75-84.
30. Sim JJ, Lac PT, Liu IL, Meguerditchian SO, Kumar VA, Kujubu DA, Rasgon SA. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010; 89: 447-52.
31. Rianthavorn P and Boonyapapong P. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr Nephrol 2013; 28: 1261-6.
32. Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, Nathan I. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 2002; 30: 403-9.
33. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D and Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 514-8.
34. Saab G, Young DO, Gincherman Y, Giles K, Norwood K and Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: c132-8.
35. Salum E, Kampus P, Zilmer M, Eha J, Butlin M, Avolio AP, Põdramägi T, Arend A, Aunapuu M, Kals J. Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes. Cardiovasc Diabetol 2012; 11: 58.
36. Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, Cussigh A, Occhino G, Baccarani U, Pirisi M, Toniutto P. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-44.
37. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR and Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-90.
38. Nimer A and Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012; 18: 800-5.
39. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 Suppl 1: 67-75.
40. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-62.
41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
42. Canonico PG, Kastello MD, Spears CT, Brown JR, Jackson EA and Jenkins DE. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74: 155-62.
43. Canonico PG, Kastello MD, Cosgriff TM, Donovan JC, Ross PE, Spears CT, Stephen EL. Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol Appl Pharmacol 1984; 74: 163-72.
44. Cosgriff TM, Hodgson LA, Canonico PG, White JD, Kastello MD, Donovan JC, Ross PE. Morphological alterations in blood and bone marrow of ribavirin-treated monkeys. Acta Haematol 1984; 72: 195-200.
45. D’Souza UJ and Narayana K. Mechanism of cytotoxicity of ribavirin in the rat bone marrow and testis. Indian J Physiol Pharmacol 2002; 46: 468-74.
46. Narayana K, D’Souza UJ and Seetharama Rao KP. The genotoxic and cytotoxic effects of ribavirin in rat bone marrow. Mutat Res 2002; 521: 179-85.